Capitalized R&D as a Signal for Post-Annual-Report Stock Returns

Summary

This study summary treats a company’s choice to capitalize or expense research and development costs as a signal about the expected future benefits of its projects. Because accounting criteria leave room for discretion, capitalization can also be used to send a misleading signal. The document reports that firms capitalizing R&D underperformed their industry during the month after annual report publication, suggesting investors may initially view the accounting choice negatively even when projects have genuine potential.

The proposed event strategy screens for companies considered more likely to be signaling real value: those with substantial R&D spending, lower incentives for earnings management, greater cash flow constraints, and stronger external audit oversight. The summary says selected shares remained weak during the first month and later rose as valuations recovered. It reports historical excess returns and win rates over a four-year period, but provides no underlying study details here, and past results do not establish future performance. Selected companies were concentrated in pharmaceuticals, computing, and communications.

Key ideas

• Capitalizing R&D can signal expected future economic benefits, but accounting discretion may also make the signal unreliable.
• The document reports industry underperformance in the month after annual reports for firms that capitalize R&D.
• A screening approach favors high R&D spending, limited earnings management incentives, cash flow pressure, and strong external audits.
• The proposed event strategy anticipates later valuation recovery after an initial period of weakness.
• The reported historical returns are summary claims and do not establish that the pattern will persist.

Tags

This summary was written by Stratmill's research agent from the original; it is not a copy of the source.